CA2706659A1 - Hcv ns3 protease replicon shuttle vectors - Google Patents
Hcv ns3 protease replicon shuttle vectors Download PDFInfo
- Publication number
- CA2706659A1 CA2706659A1 CA2706659A CA2706659A CA2706659A1 CA 2706659 A1 CA2706659 A1 CA 2706659A1 CA 2706659 A CA2706659 A CA 2706659A CA 2706659 A CA2706659 A CA 2706659A CA 2706659 A1 CA2706659 A1 CA 2706659A1
- Authority
- CA
- Canada
- Prior art keywords
- hcv
- hcv replicon
- shuttle vector
- replicon shuttle
- plasmids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000013605 shuttle vector Substances 0.000 title claims abstract description 83
- 108091005804 Peptidases Proteins 0.000 title claims description 30
- 239000004365 Protease Substances 0.000 title claims description 29
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title claims 12
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 50
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 50
- 239000002157 polynucleotide Substances 0.000 claims abstract description 49
- 238000010367 cloning Methods 0.000 claims abstract description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 51
- 239000013612 plasmid Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 38
- 108091008146 restriction endonucleases Proteins 0.000 claims description 33
- 230000010076 replication Effects 0.000 claims description 30
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 28
- 239000002773 nucleotide Substances 0.000 claims description 18
- 125000003729 nucleotide group Chemical group 0.000 claims description 18
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 claims description 17
- 208000015181 infectious disease Diseases 0.000 claims description 16
- 238000000338 in vitro Methods 0.000 claims description 13
- 230000000692 anti-sense effect Effects 0.000 claims description 12
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 claims description 11
- 238000013518 transcription Methods 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 10
- 101000600434 Homo sapiens Putative uncharacterized protein encoded by MIR7-3HG Proteins 0.000 claims description 9
- 108060004795 Methyltransferase Proteins 0.000 claims description 9
- 102100037401 Putative uncharacterized protein encoded by MIR7-3HG Human genes 0.000 claims description 9
- 108091081021 Sense strand Proteins 0.000 claims description 8
- 230000001131 transforming effect Effects 0.000 claims description 8
- 101800001020 Non-structural protein 4A Proteins 0.000 claims description 6
- 101800001014 Non-structural protein 5A Proteins 0.000 claims description 5
- 101800001019 Non-structural protein 4B Proteins 0.000 claims description 4
- 238000011176 pooling Methods 0.000 claims description 4
- 101710144111 Non-structural protein 3 Proteins 0.000 claims 14
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 abstract description 15
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000012360 testing method Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 27
- 102000035195 Peptidases Human genes 0.000 description 18
- 239000013598 vector Substances 0.000 description 18
- 235000019419 proteases Nutrition 0.000 description 17
- 241000700605 Viruses Species 0.000 description 15
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 12
- 108010076039 Polyproteins Proteins 0.000 description 12
- 230000003612 virological effect Effects 0.000 description 10
- 102000053602 DNA Human genes 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 108020005345 3' Untranslated Regions Proteins 0.000 description 8
- 241000711557 Hepacivirus Species 0.000 description 8
- 108020003589 5' Untranslated Regions Proteins 0.000 description 7
- 241000710778 Pestivirus Species 0.000 description 7
- 102000012479 Serine Proteases Human genes 0.000 description 7
- 108010022999 Serine Proteases Proteins 0.000 description 7
- 108091027544 Subgenomic mRNA Proteins 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108090000331 Firefly luciferases Proteins 0.000 description 6
- 101150038760 Ns3 gene Proteins 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- 241000710188 Encephalomyocarditis virus Species 0.000 description 5
- 241000711549 Hepacivirus C Species 0.000 description 5
- 108010067390 Viral Proteins Proteins 0.000 description 5
- -1 consist of p7 Proteins 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 238000012247 phenotypical assay Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 241000710781 Flaviviridae Species 0.000 description 2
- 241000710831 Flavivirus Species 0.000 description 2
- 241000711553 Hepatitis C virus (isolate H) Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 101150066555 lacZ gene Proteins 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- VVKVBQDZJLGAFG-UHFFFAOYSA-N 3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(CCC(O)=O)C2=C1 VVKVBQDZJLGAFG-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108010017640 Aspartic Acid Proteases Proteins 0.000 description 1
- 102000004580 Aspartic Acid Proteases Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039791 Hepatitis C virus nucleocapsid Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108030002536 RNA-directed RNA polymerases Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 241000288726 Soricidae Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108700010756 Viral Polyproteins Proteins 0.000 description 1
- 101900322197 Yellow fever virus Serine protease NS3 Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 108700008776 hepatitis C virus NS-5 Proteins 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 208000013206 susceptibility to hepatitis C virus Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000006514 viral protein processing Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24241—Use of virus, viral particle or viral elements as a vector
- C12N2770/24243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
- G01N2333/186—Hepatitis C; Hepatitis NANB
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides for novel HCV NS3 protease replicon shuttle vectors useful for cloning in HCV
polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.
polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility.
Description
This invention pertains to novel HCV NS3 protease replicon shuttle vectors which are useful for screening, testing and evaluating HCV and other Flavivirus protease inhibitors.
Hepatitis C virus is a major health problem and the leading cause of chronic liver disease throughout the world. (Boyer, N. et al. J. Hepatol. 2000 32:98-112). Patients infected with HCV are at risk of developing cirrhosis of the liver and subsequent hepatocellular carcinoma and hence HCV is the major indication for liver transplantation.
According to the World Health Organization, there are more than 200 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest can harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their offspring. Current treatments for HCV
infection, which are restricted to immunotherapy with recombinant interferon-a alone or in combination with the nucleoside analog ribavirin, are of limited clinical benefit particularly for genotype 1.
There is an urgent need for improved therapeutic agents that effectively combat chronic HCV
infection HCV has been classified as a member of the virus family Flaviviridae that includes the genera flaviviruses, pestiviruses, and hepaciviruses which includes hepatitis C viruses (Rice, C. M., Flaviviridae: The viruses and their replication, in: Fields Virology, Editors: Fields, B.
N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 30, 931-959, 1996). HCV is an enveloped virus containing a positive-sense single-stranded RNA genome of approximately 9.4 kb. The viral genome consists of a 5'-untranslated region (UTR), a long open reading frame encoding a polyprotein precursor of-approximately 3011 amino acids, and a short 3' UTR. The 5' UTR is the most highly conserved part of the HCV genome and is important for the initiation and control of polyprotein translation.
Genetic analysis of HCV has identified six main genotypes showing a >30%
divergence in the DNA sequence. Each genotype contains a series of more closely related subtypes which show a 20-25 % divergence in nucleotide sequences (Simmonds, P. 2004 J. Gen.
Virol.
85:3173-88) . More than 30 subtypes have been distinguished. In the US
approximately 70%
of infected individuals have type la and lb infection. Type lb is the most prevalent subtype in Asia. (X. Forns and J. Bukh, Clinics in Liver Disease 1999 3:693-716; J.
Bukh et at., Semin. Liv. Dis. 1995 15:41-63). Unfortunately Type 1 infections are less responsive to the current therapy than either type 2 or 3 genotypes (N. N. Zein, Clin.
Microbiol. Rev., 2000 13:223-235).
The genetic organization and polyprotein processing of the nonstructural protein portion of the ORF of pestiviruses and hepaciviruses is very similar. These positive stranded RNA
viruses possess a single large open reading frame (ORF) encoding all the viral proteins necessary for virus replication. These proteins are expressed as a polyprotein that is co- and post-translationally processed by both cellular and virus-encoded proteinases to yield the mature viral proteins. The viral proteins responsible for the replication of the viral genome RNA are located towards the carboxy-terminal. Two-thirds of the ORF are termed nonstructural (NS) proteins. For both the pestiviruses and hepaciviruses, the mature nonstructural (NS) proteins, in sequential order from the amino-terminus of the nonstructural protein coding region to the carboxy-terminus of the ORF, consist of p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B.
The NS proteins of pestiviruses and hepaciviruses share sequence domains that are characteristic of specific protein functions. For example, the NS3 proteins of viruses in both groups possess amino acid sequence motifs characteristic of serine proteinases and of helicases (Gorbalenya et at. Nature 1988 333:22; Bazan and Fletterick Virology 171:637-639; Gorbalenya et at. Nucleic Acid Res. 1989 17.3889-3897).
Similarly, the NS5B
proteins of pestiviruses and hepaciviruses have the motifs characteristic of RNA-directed RNA polymerases (Koonin, E. V. and Do1ja, V. V. Crit. Rev. Biochem. Molec.
Biol. 1993 28:375-430).
The actual roles and functions of the NS proteins of pestiviruses and hepaciviruses in the lifecycle of the viruses are directly analogous. In both cases, the NS3 serine proteinase is responsible for all proteolytic processing of polyprotein precursors downstream of its position in the ORF (Wiskerchen and Collett Virology 1991 184:341-350; Bartenschlager et at. J.
Virol. 1993 67:3835-3844; Eckart et at. Biochem. Biophys. Res. Comm. 1993 192:399-406;
Hepatitis C virus is a major health problem and the leading cause of chronic liver disease throughout the world. (Boyer, N. et al. J. Hepatol. 2000 32:98-112). Patients infected with HCV are at risk of developing cirrhosis of the liver and subsequent hepatocellular carcinoma and hence HCV is the major indication for liver transplantation.
According to the World Health Organization, there are more than 200 million infected individuals worldwide, with at least 3 to 4 million people being infected each year. Once infected, about 20% of people clear the virus, but the rest can harbor HCV the rest of their lives. Ten to twenty percent of chronically infected individuals eventually develop liver-destroying cirrhosis or cancer. The viral disease is transmitted parenterally by contaminated blood and blood products, contaminated needles, or sexually and vertically from infected mothers or carrier mothers to their offspring. Current treatments for HCV
infection, which are restricted to immunotherapy with recombinant interferon-a alone or in combination with the nucleoside analog ribavirin, are of limited clinical benefit particularly for genotype 1.
There is an urgent need for improved therapeutic agents that effectively combat chronic HCV
infection HCV has been classified as a member of the virus family Flaviviridae that includes the genera flaviviruses, pestiviruses, and hepaciviruses which includes hepatitis C viruses (Rice, C. M., Flaviviridae: The viruses and their replication, in: Fields Virology, Editors: Fields, B.
N., Knipe, D. M., and Howley, P. M., Lippincott-Raven Publishers, Philadelphia, Pa., Chapter 30, 931-959, 1996). HCV is an enveloped virus containing a positive-sense single-stranded RNA genome of approximately 9.4 kb. The viral genome consists of a 5'-untranslated region (UTR), a long open reading frame encoding a polyprotein precursor of-approximately 3011 amino acids, and a short 3' UTR. The 5' UTR is the most highly conserved part of the HCV genome and is important for the initiation and control of polyprotein translation.
Genetic analysis of HCV has identified six main genotypes showing a >30%
divergence in the DNA sequence. Each genotype contains a series of more closely related subtypes which show a 20-25 % divergence in nucleotide sequences (Simmonds, P. 2004 J. Gen.
Virol.
85:3173-88) . More than 30 subtypes have been distinguished. In the US
approximately 70%
of infected individuals have type la and lb infection. Type lb is the most prevalent subtype in Asia. (X. Forns and J. Bukh, Clinics in Liver Disease 1999 3:693-716; J.
Bukh et at., Semin. Liv. Dis. 1995 15:41-63). Unfortunately Type 1 infections are less responsive to the current therapy than either type 2 or 3 genotypes (N. N. Zein, Clin.
Microbiol. Rev., 2000 13:223-235).
The genetic organization and polyprotein processing of the nonstructural protein portion of the ORF of pestiviruses and hepaciviruses is very similar. These positive stranded RNA
viruses possess a single large open reading frame (ORF) encoding all the viral proteins necessary for virus replication. These proteins are expressed as a polyprotein that is co- and post-translationally processed by both cellular and virus-encoded proteinases to yield the mature viral proteins. The viral proteins responsible for the replication of the viral genome RNA are located towards the carboxy-terminal. Two-thirds of the ORF are termed nonstructural (NS) proteins. For both the pestiviruses and hepaciviruses, the mature nonstructural (NS) proteins, in sequential order from the amino-terminus of the nonstructural protein coding region to the carboxy-terminus of the ORF, consist of p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B.
The NS proteins of pestiviruses and hepaciviruses share sequence domains that are characteristic of specific protein functions. For example, the NS3 proteins of viruses in both groups possess amino acid sequence motifs characteristic of serine proteinases and of helicases (Gorbalenya et at. Nature 1988 333:22; Bazan and Fletterick Virology 171:637-639; Gorbalenya et at. Nucleic Acid Res. 1989 17.3889-3897).
Similarly, the NS5B
proteins of pestiviruses and hepaciviruses have the motifs characteristic of RNA-directed RNA polymerases (Koonin, E. V. and Do1ja, V. V. Crit. Rev. Biochem. Molec.
Biol. 1993 28:375-430).
The actual roles and functions of the NS proteins of pestiviruses and hepaciviruses in the lifecycle of the viruses are directly analogous. In both cases, the NS3 serine proteinase is responsible for all proteolytic processing of polyprotein precursors downstream of its position in the ORF (Wiskerchen and Collett Virology 1991 184:341-350; Bartenschlager et at. J.
Virol. 1993 67:3835-3844; Eckart et at. Biochem. Biophys. Res. Comm. 1993 192:399-406;
Grakoui et at. J. Virol. 1993 67:2832-2843; Grakoui et at. Proc. Natl. Acad.
Sci. USA 1993 90:10583-10587; Ilijikata et at. J. Virol. 1993 67:4665-4675; Tome et at. J.
Virol. 1993 67:4017-4026). The NS4A protein, in both cases, acts as a cofactor with the NS3 serine protease (Bartenschlager et at. J. Virol. 1994 68:5045-5055; Failla et at. J.
Virol. 1994 68:
3753-3760; Xu et at. J Virol. 1997 71:53 12-5322). The NS3 protein of both viruses also functions as a helicase (Kim et at. Biochem. Biophys. Res. Comm. 1995 215: 160-166; Jin and Peterson Arch. Biochem. Biophys. 1995, 323:47-53; Warrener and Collett J.
Virol. 1995 69:1720-1726). Finally, the NS5B proteins of pestiviruses and hepaciviruses have the predicted RNA-dependent RNA polymerase activity (Behrens et al. EMBO 1996 15:12-22;
Lechmann et at. J. Virol. 1997 71:8416-8428; Yuan et at. Biochem. Biophys.
Res. Comm.
1997 232:231-235; Hagedorn, PCT WO 97/12033; Zhong et at. J. Virol. 1998 72:9365-9369).
The HCV NS protein 3 (NS3) contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decreases viral infectivity (Chambers et. at., Proc. Natl. Acad. Sci. USA, 1990, 87:8898-8902). The first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV
polyprotein (Lin et at., J. Virol. 1994 68:8147-8157). The HCV NS3 serine protease and its associated cofactor, NS4A, helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing HIV protease inhibitors, which inhibit viral protein processing are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents. Consequently it is an attractive target for drug discovery.
Currently there are a limited number of approved therapies are currently available for the treatment of HCV infection. New and existing therapeutic approaches to treating HCV and inhibition of HCV NS5B polymerase have been reviewed: R. G. Gish, Sem. Liver.
Dis., 1999 19:5; Di Besceglie, A. M. and Bacon, B. R., Scientific American, October: 1999 80-85; G.
Lake-Bakaar, Current and Future Therapy for Chronic Hepatitis C Virus Liver Disease, Curr.
Drug Targ. Infect Dis. 2003 3(3):247-253; P. Hoffmann et at., Recent patents on experimental therapy for hepatitis C virus infection (1999-2002), Exp. Opin.
Ther. Patents 2003 13(11):1707-1723; F. F. Poordad et at. Developments in Hepatitis C
therapy during 2000-2002, Exp. Opin. Emerging Drugs 2003 8(1):9-25; M. P. Walker et at., Promising Candidates for the treatment of chronic hepatitis C, Exp. Opin. Investig.
Drugs 2003 12(8):1269-1280; S.-L. Tan et at., Hepatitis C Therapeutics: Current Status and Emerging Strategies, Nature Rev. Drug Discov. 2002 1:867-88 1; R. De Francesco et at.
Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B
RNA-dependent RNA polymerase, Antiviral Res. 2003 58:1-16; Q. M. Wang et at.
Hepatitis C virus encoded proteins: targets for antiviral therapy, Drugs of the Future 2000 25(9):933-8-944; J. A. Wu and Z. Hong, Targeting NS5B-Dependent RNA Polymerase for Anti-HCV
Chemotherapy Cur. Drug Targ.-Inf. Dis.2003 3:207-219.
Despite advances in understanding the genomic organization of the virus and the functions of viral proteins, fundamental aspects of HCV replication and pathogenesis remain unknown. A
major challenge in gaining experimental access to HCV replication is the lack of an efficient cell culture system that allows production of infectious virus particles.
Although infection of primary cell cultures and certain human cell lines has been reported, the amounts of virus produced in those systems and the levels of HCV replication have been too low to permit detailed analyses.
The construction of selectable subgenomic HCV RNAs that replicate with minimal efficiency in the human hepatoma cell line Huh-7 has been reported. Lohman et al.
reported the construction of a replicon (I 377/NS3-3') derived from a cloned full-length HCV consensus genome (genotype lb) by deleting the C-p7 or C-NS2 region of the protein-coding region (Lohman et al., Science 1999 285: 110-113). The replicon contained the following elements:
(i) the HCV 5'-UTR fused to 12 amino acids of the capsid encoding region; (ii) the neomycin phosphotransferace gene (NPTII); (iii) the IRES from encephalomyocarditis virus (EMCV), inserted downstream of the NPTII gene and which directs translation of HCV
proteins NS2 or NS3 to NS5B; and (iv) the 3'-UTR. After transfection of Huh-7 cells, only those cells supporting HCV RNA replication expressed the NPTII protein and developed resistance against the drug G418. While the cell lines derived from such G418 resistant colonies contained substantial levels of replicon RNAs and viral proteins, only 1 in 106 transfected Huh-7 cells supported HCV replication.
Similar selectable HCV replicons were constructed based on an HCV-H genotype 1 a infectious clone (Blight et al., Science 2000 290:1972-74). The HCV-H derived replicons were unable to establish efficient HCV replication, suggesting that the earlier-constructed replicons of Lohmann (1999), supra, were dependent on the particular genotype 1 b consensus cDNA clone used in those experiments. Blight et al. (2000), supra, reproduced the construction of the replicon made by Lohmann et al. (1999), supra, by carrying out a PCR-based gene assembly procedure and obtained G418-resistant Huh-7 cell colonies.
Independent G418-resistant cell clones were sequenced to determine whether high-level HCV
replication required adaptation of the replicon to the host cell. Multiple independent adaptive mutations that cluster in the HCV nonstructural protein NS5A were identified.
The mutations conferred increased replicative ability in vitro, with transduction efficiency ranging from 0.2 to 10% of transfected cells as compared to earlier- constructed replicons in the art, e.g., the I
377/NS3-3' replicon had a 0.0001% transduction efficiency.
The present invention features the development of a novel HCV replicon shuttle vector in which unique restriction enzyme sites are introduced at the 5' and 3' ends of the protease domain of the NS3 gene such that NS3 protease sequences derived from the samples of HCV-infected patients can be cloned in the shuttle vector and the resulting replicons be evaluated for replication fitness and susceptibility to HCV NS3 protease inhibitors. Since an individual HCV-infected patient typically contains a genetically diverse virus population due to the high error rate of the NS5B RNA polymerase, the use of the shuttle vector of the present invention would allow the characterization of specific patient-derived NS3 protease variants and the sensitivity or resistance of these variants to drug treatment.
Accordingly, the present invention provides an HCV replicon shuttle vector comprising an HCV polynucleotide sequence comprising, in order, a unique restriction enzyme sequence placed between 10 nucleotides 5' and 10 nucleotides 3' from the 5' end of a polynucleotide sequence encoding a NS3 protein; a polynucleotide sequence encoding the protease domain of the NS3 protein; a unique restriction enzyme sequence placed between 10 nucleotides 5' and 10 nucleotides 3' from the 3' end of the polynucleotide sequence encoding the protease domain of the NS3 protein; a polynucleotide sequence encoding the helicase domain of the NS3 protein;
a polynucleotide sequence encoding a NS4A protein; a polynucleotide sequence encoding a NS4B protein; a polynucleotide sequence encoding a NS5A protein; and a polynucleotide sequence encoding a NS5B protein. In one embodiment of the invention, the polynucleotide sequence encoding the protease domain of the NS3 protein has been modified or deleted such that the protease domain of the NS3 protein is non-functional.
Sci. USA 1993 90:10583-10587; Ilijikata et at. J. Virol. 1993 67:4665-4675; Tome et at. J.
Virol. 1993 67:4017-4026). The NS4A protein, in both cases, acts as a cofactor with the NS3 serine protease (Bartenschlager et at. J. Virol. 1994 68:5045-5055; Failla et at. J.
Virol. 1994 68:
3753-3760; Xu et at. J Virol. 1997 71:53 12-5322). The NS3 protein of both viruses also functions as a helicase (Kim et at. Biochem. Biophys. Res. Comm. 1995 215: 160-166; Jin and Peterson Arch. Biochem. Biophys. 1995, 323:47-53; Warrener and Collett J.
Virol. 1995 69:1720-1726). Finally, the NS5B proteins of pestiviruses and hepaciviruses have the predicted RNA-dependent RNA polymerase activity (Behrens et al. EMBO 1996 15:12-22;
Lechmann et at. J. Virol. 1997 71:8416-8428; Yuan et at. Biochem. Biophys.
Res. Comm.
1997 232:231-235; Hagedorn, PCT WO 97/12033; Zhong et at. J. Virol. 1998 72:9365-9369).
The HCV NS protein 3 (NS3) contains a serine protease activity that helps process the majority of the viral enzymes, and is thus considered essential for viral replication and infectivity. It is known that mutations in the yellow fever virus NS3 protease decreases viral infectivity (Chambers et. at., Proc. Natl. Acad. Sci. USA, 1990, 87:8898-8902). The first 181 amino acids of NS3 (residues 1027-1207 of the viral polyprotein) have been shown to contain the serine protease domain of NS3 that processes all four downstream sites of the HCV
polyprotein (Lin et at., J. Virol. 1994 68:8147-8157). The HCV NS3 serine protease and its associated cofactor, NS4A, helps process all of the viral enzymes, and is thus considered essential for viral replication. This processing appears to be analogous to that carried out by the human immunodeficiency virus aspartyl protease, which is also involved in viral enzyme processing HIV protease inhibitors, which inhibit viral protein processing are potent antiviral agents in man, indicating that interrupting this stage of the viral life cycle results in therapeutically active agents. Consequently it is an attractive target for drug discovery.
Currently there are a limited number of approved therapies are currently available for the treatment of HCV infection. New and existing therapeutic approaches to treating HCV and inhibition of HCV NS5B polymerase have been reviewed: R. G. Gish, Sem. Liver.
Dis., 1999 19:5; Di Besceglie, A. M. and Bacon, B. R., Scientific American, October: 1999 80-85; G.
Lake-Bakaar, Current and Future Therapy for Chronic Hepatitis C Virus Liver Disease, Curr.
Drug Targ. Infect Dis. 2003 3(3):247-253; P. Hoffmann et at., Recent patents on experimental therapy for hepatitis C virus infection (1999-2002), Exp. Opin.
Ther. Patents 2003 13(11):1707-1723; F. F. Poordad et at. Developments in Hepatitis C
therapy during 2000-2002, Exp. Opin. Emerging Drugs 2003 8(1):9-25; M. P. Walker et at., Promising Candidates for the treatment of chronic hepatitis C, Exp. Opin. Investig.
Drugs 2003 12(8):1269-1280; S.-L. Tan et at., Hepatitis C Therapeutics: Current Status and Emerging Strategies, Nature Rev. Drug Discov. 2002 1:867-88 1; R. De Francesco et at.
Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B
RNA-dependent RNA polymerase, Antiviral Res. 2003 58:1-16; Q. M. Wang et at.
Hepatitis C virus encoded proteins: targets for antiviral therapy, Drugs of the Future 2000 25(9):933-8-944; J. A. Wu and Z. Hong, Targeting NS5B-Dependent RNA Polymerase for Anti-HCV
Chemotherapy Cur. Drug Targ.-Inf. Dis.2003 3:207-219.
Despite advances in understanding the genomic organization of the virus and the functions of viral proteins, fundamental aspects of HCV replication and pathogenesis remain unknown. A
major challenge in gaining experimental access to HCV replication is the lack of an efficient cell culture system that allows production of infectious virus particles.
Although infection of primary cell cultures and certain human cell lines has been reported, the amounts of virus produced in those systems and the levels of HCV replication have been too low to permit detailed analyses.
The construction of selectable subgenomic HCV RNAs that replicate with minimal efficiency in the human hepatoma cell line Huh-7 has been reported. Lohman et al.
reported the construction of a replicon (I 377/NS3-3') derived from a cloned full-length HCV consensus genome (genotype lb) by deleting the C-p7 or C-NS2 region of the protein-coding region (Lohman et al., Science 1999 285: 110-113). The replicon contained the following elements:
(i) the HCV 5'-UTR fused to 12 amino acids of the capsid encoding region; (ii) the neomycin phosphotransferace gene (NPTII); (iii) the IRES from encephalomyocarditis virus (EMCV), inserted downstream of the NPTII gene and which directs translation of HCV
proteins NS2 or NS3 to NS5B; and (iv) the 3'-UTR. After transfection of Huh-7 cells, only those cells supporting HCV RNA replication expressed the NPTII protein and developed resistance against the drug G418. While the cell lines derived from such G418 resistant colonies contained substantial levels of replicon RNAs and viral proteins, only 1 in 106 transfected Huh-7 cells supported HCV replication.
Similar selectable HCV replicons were constructed based on an HCV-H genotype 1 a infectious clone (Blight et al., Science 2000 290:1972-74). The HCV-H derived replicons were unable to establish efficient HCV replication, suggesting that the earlier-constructed replicons of Lohmann (1999), supra, were dependent on the particular genotype 1 b consensus cDNA clone used in those experiments. Blight et al. (2000), supra, reproduced the construction of the replicon made by Lohmann et al. (1999), supra, by carrying out a PCR-based gene assembly procedure and obtained G418-resistant Huh-7 cell colonies.
Independent G418-resistant cell clones were sequenced to determine whether high-level HCV
replication required adaptation of the replicon to the host cell. Multiple independent adaptive mutations that cluster in the HCV nonstructural protein NS5A were identified.
The mutations conferred increased replicative ability in vitro, with transduction efficiency ranging from 0.2 to 10% of transfected cells as compared to earlier- constructed replicons in the art, e.g., the I
377/NS3-3' replicon had a 0.0001% transduction efficiency.
The present invention features the development of a novel HCV replicon shuttle vector in which unique restriction enzyme sites are introduced at the 5' and 3' ends of the protease domain of the NS3 gene such that NS3 protease sequences derived from the samples of HCV-infected patients can be cloned in the shuttle vector and the resulting replicons be evaluated for replication fitness and susceptibility to HCV NS3 protease inhibitors. Since an individual HCV-infected patient typically contains a genetically diverse virus population due to the high error rate of the NS5B RNA polymerase, the use of the shuttle vector of the present invention would allow the characterization of specific patient-derived NS3 protease variants and the sensitivity or resistance of these variants to drug treatment.
Accordingly, the present invention provides an HCV replicon shuttle vector comprising an HCV polynucleotide sequence comprising, in order, a unique restriction enzyme sequence placed between 10 nucleotides 5' and 10 nucleotides 3' from the 5' end of a polynucleotide sequence encoding a NS3 protein; a polynucleotide sequence encoding the protease domain of the NS3 protein; a unique restriction enzyme sequence placed between 10 nucleotides 5' and 10 nucleotides 3' from the 3' end of the polynucleotide sequence encoding the protease domain of the NS3 protein; a polynucleotide sequence encoding the helicase domain of the NS3 protein;
a polynucleotide sequence encoding a NS4A protein; a polynucleotide sequence encoding a NS4B protein; a polynucleotide sequence encoding a NS5A protein; and a polynucleotide sequence encoding a NS5B protein. In one embodiment of the invention, the polynucleotide sequence encoding the protease domain of the NS3 protein has been modified or deleted such that the protease domain of the NS3 protein is non-functional.
In another embodiment of the invention, the unique restriction enzyme sequence at the 5' end of the polynucleotide sequence encoding the NS3 protein recognizes EcoRV and the unique restriction enzyme sequence at the 3' end of the polynucleotide sequence encoding the protease domain of the NS3 protein recognizes AsiSI. In still another embodiment of the invention, the HCV replicon shuttle vector comprises an HCV polynucleotide sequence selected from SEQ ID NO:3 or SEQ ID NO:6.
A further embodiment of the present invention provides a method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of providing a sample from the subject infected with HCV, PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence, cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV
replicon plasmids, linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs, and transfecting a Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
A still further embodiment of the present invention provides a method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of providing a sample from the subject infected with HCV, PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence, cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV
replicon plasmids, transforming said plasmids into cells to generate a plurarity of colonies of transformed cells, pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies, linearizing said chimeric HCV replicon plasmids, subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs, and transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
A further embodiment of the present invention provides a method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of providing a sample from the subject infected with HCV, PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence, cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV
replicon plasmids, linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs, and transfecting a Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
A still further embodiment of the present invention provides a method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of providing a sample from the subject infected with HCV, PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence, cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV
replicon plasmids, transforming said plasmids into cells to generate a plurarity of colonies of transformed cells, pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies, linearizing said chimeric HCV replicon plasmids, subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs, and transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
The foregoing and other advantages and features of the invention, and the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying examples, which illustrate exemplary embodiments.
Brief description of the drawings Figure 1 is a schematic representation of the components of the HCV replicon shuttle vectors.
Figure 2 shows the plasmid maps of the NS3 protease replicon shuttle vectors (A) pSC_lb_NS3/Protease_EcoRV_AsiSI (SEQ ID NO:3); (B) pSC_lb_NS3/Protease/LacZ_EcoRV_AsiSI (SEQ ID NO:6).
Figure 3 shows the replication capability ofpSC_lb_NS3/Protease_EcoRV_AsiSI as well as replicon that contain patient-derived NS3 proteases from HCV genotype-la or genotype lb.
RLU represents level of firefly luciferase signal observed after 96 hours following tranfection.
The term used in the present invention are defined below.
The term "HCV replicon" refers to a nucleic acid from the Hepatitis C virus that is capable of directing the generation of copies of itself. As used herein, the term "replicon" includes RNA
as well as DNA, and hybrids thereof. For example, double-stranded DNA versions of HCV
genomes can be used to generate a single-stranded RNA transcript that constitutes an HCV
replicon. The HCV replicons can include full length HCV genome or HCV
subgenomic contructs also referred as a "subgenomic replicon". For example, the subgenomic replicons of HCV described herein contain most of the genes for the non-structural proteins of the virus, but are missing most of the genes coding for the structural proteins.
Subgenomic replicons are capable of directing the expression of all of the viral genes necessary for the replication of the viral subgenome, replication of the sub-genomic replicon, without the production of viral particles.
A basic HCV replicon is a subgenomic construct containing an HCV 5'-untranslated (UTR) region, an HCV NS3-NS5B polyprotein encoding region, and a HCV 3'-UTR. Other nucleic acid regions can be present such as those providing for HCV NS2, structural HCV protein(s) and non-HCV sequences.
Brief description of the drawings Figure 1 is a schematic representation of the components of the HCV replicon shuttle vectors.
Figure 2 shows the plasmid maps of the NS3 protease replicon shuttle vectors (A) pSC_lb_NS3/Protease_EcoRV_AsiSI (SEQ ID NO:3); (B) pSC_lb_NS3/Protease/LacZ_EcoRV_AsiSI (SEQ ID NO:6).
Figure 3 shows the replication capability ofpSC_lb_NS3/Protease_EcoRV_AsiSI as well as replicon that contain patient-derived NS3 proteases from HCV genotype-la or genotype lb.
RLU represents level of firefly luciferase signal observed after 96 hours following tranfection.
The term used in the present invention are defined below.
The term "HCV replicon" refers to a nucleic acid from the Hepatitis C virus that is capable of directing the generation of copies of itself. As used herein, the term "replicon" includes RNA
as well as DNA, and hybrids thereof. For example, double-stranded DNA versions of HCV
genomes can be used to generate a single-stranded RNA transcript that constitutes an HCV
replicon. The HCV replicons can include full length HCV genome or HCV
subgenomic contructs also referred as a "subgenomic replicon". For example, the subgenomic replicons of HCV described herein contain most of the genes for the non-structural proteins of the virus, but are missing most of the genes coding for the structural proteins.
Subgenomic replicons are capable of directing the expression of all of the viral genes necessary for the replication of the viral subgenome, replication of the sub-genomic replicon, without the production of viral particles.
A basic HCV replicon is a subgenomic construct containing an HCV 5'-untranslated (UTR) region, an HCV NS3-NS5B polyprotein encoding region, and a HCV 3'-UTR. Other nucleic acid regions can be present such as those providing for HCV NS2, structural HCV protein(s) and non-HCV sequences.
The HCV 5'-UTR region provides an internal ribosome entry site (IRES) for protein translation and elements needed for replication. The HCV 5'-UTR region includes naturally occurring HCV 5'-UTR extending about 36 nucleotides into a HCV core encoding region, and functional derivatives thereof. The 5'-UTR region can be present in different locations such as site downstream from a sequence encoding a selection protein, a reporter, protein, or an HCV polyprotein.
In addition to the HCV 5'-UTR-PC region, non-HCV IRES elements can also be present in the replicon. The non-HCV IRES elements can be present in different locations including immediately upstream the region encoding for an HCV polyprotein. Examples of non-HCV
IRES elements that can be used are the EMCV IRES, poliovirus IRES, and bovine viral diarrhea virus IRES.
The HCV 3'-UTR assists HCV replication. HCV 3' UTR includes naturally occurring HCV
3'-UTR and functional derivatives thereof. Naturally occurring 3'-UTRs include a poly U
tract and an additional region of about 100 nucleotides.
The NS3-NS5B polyprotein encoding region provides for a polyprotein that can be processed in a cell into different proteins. Suitable NS3-NS5B polyprotein sequences that may be part of a replicon include those present in different HCV strains and functional equivalents thereof resulting in the processing of NS3-NS5B to produce a functional replication machinery.
Proper processing can be measured for by assaying, for example, NS5B RNA
dependent RNA polymerase.
A "vector" is a piece of DNA, such as a plasmid, phage or cosmid, to which another piece of DNA segment may be attached so as to bring about the replication, expression or integration of the attached DNA segment. A "shuttle vector" refers to a vector in which a DNA segment can be inserted into or excised from a vector at specific restriction enzyme sites. The segment of DNA that is inserted into shuttle vector generally encodes a polypeptide or RNA
of interest and the restriction enzyme sites are designed to ensure insertion of the DNA
segment in the proper reading frame for transcription and translation.
A variety of vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, herpes viruses, and retroviruses. Vectors may also be derived from combinations of these sources, such as those derived from plasmid and bacteriophage genetic elements, e.g., cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual. 2nd edn.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA.
A vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using known techniques.
Host cells can include bacterial cells including, but not limited to, E. coli, Streptomyces, and Salmonella typhimurium, eukaryotic cells including, but not limited to, yeast, insect cells, such as Drosophila, animal cells, such as Huh-7, HeLa, COS, HEK 293, MT- 2T, CEM-SS, and CHO cells, and plant cells.
Vectors generally include selectable markers that enable the selection of a subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline- or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells.
However, any marker that provides selection for a phenotypic trait will be effective.
A "polynucleotide" or "nucleic acid molecule" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
"Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
In addition, the term "DNA molecule" refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, the term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA
(i.e., the strand having a sequence homologous to the mRNA).
An "RNA molecule" refers to the polymeric form of ribonucleotides in its either single-stranded form or a double-stranded helix form. In discussing the structure of particular RNA
molecules, sequence may be described herein according to the normal convention of giving the sequence in the 5' to 3' direction.
The term "restriction enzyme sequence" refers to a specific double stranded-DNA sequence which is recognized and cut by bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence. The restriction enzyme "EcoRV"
recognizes the sequence 5' GAT'ATC 3' and cuts the double-stranded DNA at the indicated 3' CTAATAG 5' nucleotide position (shown with ' A). The restriction enzyme "AsiSI"
recognizes the sequence 5' GCGAT'CGC 3' and cuts after the T residue on the recognition sequence.
3' CGCATAGCG 5' The term "primer" as used herein refers to an oligonucleotide, either RNA or DNA, either single-stranded or double-stranded, either derived from a biological system, generated by restriction enzyme digestion, or produced synthetically which, when placed in the proper environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis. When presented with an appropriate nucleic acid template, suitable nucleoside triphosphate precursors of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as a suitable temperature and pH, the primer may be extended at its 3' terminus by the addition of nucleotides by the action of a polymerase or similar activity to yield a primer extension product. The primer may vary in length depending on the particular conditions and requirement of the application. For example, in PCR reactions, the primer is typically 15-25 nucleotides or longer in length. The primer must be of sufficient complementarity to the desired template to prime the synthesis of the desired extension product, i.e. to be able to anneal with the desired template strand in a manner sufficient to provide the 3'-hydroxyl moiety of the primer in appropriate juxtaposition for use in the initiation of synthesis by a polymerase or similar enzyme. It is not required that the primer sequence represent an exact complement of the desired template. For example, a non-complementary nucleotide sequence (e.g. a restriction enzyme recognition sequence) may be attached to the 5'-end of an otherwise complementary primer. Alternatively, non-complementary bases may be interspersed within the oligonucleotide primer sequence, provided that the primer sequence has sufficient complementarity with the sequence of the desired template strand to functionally provide a template-primer complex for the synthesis of the extension product.
The term "chimeric" as used herein means a molecule of DNA that has resulted from DNA
from two or more different sources that have been fused or spliced together.
As used herein, the term "quasispecies" means a collection of microvariants of a predominant HCV genome sequence (i.e. genotype), said microvariants being formed in a single infected subject or even in a single cell clone or even in a single cell clone as a result of high mutation rate during HCV replication.
The term "subject" as used herein refers to vertebrates, particular members of the mammalian species and includes, but not limited to, rodents, rabbits, shrews, and primates, the latter including humans.
The term "sample" refers to a sample of tissue or fluid isolated from a subject, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vitro cell culture constituents (including but not limited to, conditioned medium resulting from the growth of cultured cells, putatively viral infected cells, recombinant cells, and cell components).
A cell has been "transformed" or "transfected" by exogenous or heterologous DNA or RNA
when such DNA or RNA has been introduced inside the cell. The transforming or transfecting DNA or RNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. For example, in prokaryotes, yeast, and mammalian cells, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. In the case of an HCV replicon that transforms a mammalian cell as described in the present invention, the RNA molecule, e.g., an HCV RNA
molecule, has the ability to replicate semi-autonomously. Huh-7 cells carrying the HCV
In addition to the HCV 5'-UTR-PC region, non-HCV IRES elements can also be present in the replicon. The non-HCV IRES elements can be present in different locations including immediately upstream the region encoding for an HCV polyprotein. Examples of non-HCV
IRES elements that can be used are the EMCV IRES, poliovirus IRES, and bovine viral diarrhea virus IRES.
The HCV 3'-UTR assists HCV replication. HCV 3' UTR includes naturally occurring HCV
3'-UTR and functional derivatives thereof. Naturally occurring 3'-UTRs include a poly U
tract and an additional region of about 100 nucleotides.
The NS3-NS5B polyprotein encoding region provides for a polyprotein that can be processed in a cell into different proteins. Suitable NS3-NS5B polyprotein sequences that may be part of a replicon include those present in different HCV strains and functional equivalents thereof resulting in the processing of NS3-NS5B to produce a functional replication machinery.
Proper processing can be measured for by assaying, for example, NS5B RNA
dependent RNA polymerase.
A "vector" is a piece of DNA, such as a plasmid, phage or cosmid, to which another piece of DNA segment may be attached so as to bring about the replication, expression or integration of the attached DNA segment. A "shuttle vector" refers to a vector in which a DNA segment can be inserted into or excised from a vector at specific restriction enzyme sites. The segment of DNA that is inserted into shuttle vector generally encodes a polypeptide or RNA
of interest and the restriction enzyme sites are designed to ensure insertion of the DNA
segment in the proper reading frame for transcription and translation.
A variety of vectors can be used to express a nucleic acid molecule. Such vectors include chromosomal, episomal, and virus-derived vectors, e.g., vectors derived from bacterial plasmids, from bacteriophage, from yeast episomes, from yeast chromosomal elements, including yeast artificial chromosomes, from viruses such as baculoviruses, papovaviruses such as SV40, vaccinia viruses, adenoviruses, poxviruses, pseudorabies viruses, herpes viruses, and retroviruses. Vectors may also be derived from combinations of these sources, such as those derived from plasmid and bacteriophage genetic elements, e.g., cosmids and phagemids. Appropriate cloning and expression vectors for prokaryotic and eukaryotic hosts are described in Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual. 2nd edn.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA.
A vector containing the appropriate nucleic acid molecule can be introduced into an appropriate host cell for propagation or expression using known techniques.
Host cells can include bacterial cells including, but not limited to, E. coli, Streptomyces, and Salmonella typhimurium, eukaryotic cells including, but not limited to, yeast, insect cells, such as Drosophila, animal cells, such as Huh-7, HeLa, COS, HEK 293, MT- 2T, CEM-SS, and CHO cells, and plant cells.
Vectors generally include selectable markers that enable the selection of a subpopulation of cells that contain the recombinant vector constructs. The marker can be contained in the same vector that contains the nucleic acid molecules described herein or may be on a separate vector. Markers include tetracycline- or ampicillin-resistance genes for prokaryotic host cells and dihydrofolate reductase or neomycin resistance for eukaryotic host cells.
However, any marker that provides selection for a phenotypic trait will be effective.
A "polynucleotide" or "nucleic acid molecule" generally refers to any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA.
"Polynucleotides" include, without limitation single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, "polynucleotide" refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. "Polynucleotide" also embraces relatively short polynucleotides, often referred to as oligonucleotides.
In addition, the term "DNA molecule" refers only to the primary and secondary structure of the molecule, and does not limit it to any particular tertiary forms. Thus, the term includes double-stranded DNA found, inter alia, in linear DNA molecules (e.g., restriction fragments), viruses, plasmids, and chromosomes. In discussing the structure of particular double-stranded DNA molecules, sequences may be described herein according to the normal convention of giving only the sequence in the 5' to 3' direction along the nontranscribed strand of DNA
(i.e., the strand having a sequence homologous to the mRNA).
An "RNA molecule" refers to the polymeric form of ribonucleotides in its either single-stranded form or a double-stranded helix form. In discussing the structure of particular RNA
molecules, sequence may be described herein according to the normal convention of giving the sequence in the 5' to 3' direction.
The term "restriction enzyme sequence" refers to a specific double stranded-DNA sequence which is recognized and cut by bacterial enzymes, each of which cut double-stranded DNA at or near a specific nucleotide sequence. The restriction enzyme "EcoRV"
recognizes the sequence 5' GAT'ATC 3' and cuts the double-stranded DNA at the indicated 3' CTAATAG 5' nucleotide position (shown with ' A). The restriction enzyme "AsiSI"
recognizes the sequence 5' GCGAT'CGC 3' and cuts after the T residue on the recognition sequence.
3' CGCATAGCG 5' The term "primer" as used herein refers to an oligonucleotide, either RNA or DNA, either single-stranded or double-stranded, either derived from a biological system, generated by restriction enzyme digestion, or produced synthetically which, when placed in the proper environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis. When presented with an appropriate nucleic acid template, suitable nucleoside triphosphate precursors of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as a suitable temperature and pH, the primer may be extended at its 3' terminus by the addition of nucleotides by the action of a polymerase or similar activity to yield a primer extension product. The primer may vary in length depending on the particular conditions and requirement of the application. For example, in PCR reactions, the primer is typically 15-25 nucleotides or longer in length. The primer must be of sufficient complementarity to the desired template to prime the synthesis of the desired extension product, i.e. to be able to anneal with the desired template strand in a manner sufficient to provide the 3'-hydroxyl moiety of the primer in appropriate juxtaposition for use in the initiation of synthesis by a polymerase or similar enzyme. It is not required that the primer sequence represent an exact complement of the desired template. For example, a non-complementary nucleotide sequence (e.g. a restriction enzyme recognition sequence) may be attached to the 5'-end of an otherwise complementary primer. Alternatively, non-complementary bases may be interspersed within the oligonucleotide primer sequence, provided that the primer sequence has sufficient complementarity with the sequence of the desired template strand to functionally provide a template-primer complex for the synthesis of the extension product.
The term "chimeric" as used herein means a molecule of DNA that has resulted from DNA
from two or more different sources that have been fused or spliced together.
As used herein, the term "quasispecies" means a collection of microvariants of a predominant HCV genome sequence (i.e. genotype), said microvariants being formed in a single infected subject or even in a single cell clone or even in a single cell clone as a result of high mutation rate during HCV replication.
The term "subject" as used herein refers to vertebrates, particular members of the mammalian species and includes, but not limited to, rodents, rabbits, shrews, and primates, the latter including humans.
The term "sample" refers to a sample of tissue or fluid isolated from a subject, including but not limited to, for example, plasma, serum, spinal fluid, lymph fluid, the external sections of the skin, respiratory, intestinal and genitourinary tracts, tears, saliva, milk, blood cells, tumors, organs, and also samples of in vitro cell culture constituents (including but not limited to, conditioned medium resulting from the growth of cultured cells, putatively viral infected cells, recombinant cells, and cell components).
A cell has been "transformed" or "transfected" by exogenous or heterologous DNA or RNA
when such DNA or RNA has been introduced inside the cell. The transforming or transfecting DNA or RNA may or may not be integrated (covalently linked) into chromosomal DNA making up the genome of the cell. For example, in prokaryotes, yeast, and mammalian cells, the transforming DNA may be maintained on an episomal element such as a plasmid. With respect to eukaryotic cells, a stably transformed cell is one in which the transforming DNA has become integrated into a chromosome so that it is inherited by daughter cells through chromosome replication. This stability is demonstrated by the ability of the eukaryotic cell to establish cell lines or clones comprised of a population of daughter cells containing the transforming DNA. In the case of an HCV replicon that transforms a mammalian cell as described in the present invention, the RNA molecule, e.g., an HCV RNA
molecule, has the ability to replicate semi-autonomously. Huh-7 cells carrying the HCV
replicons are detected either by the presence of a selection marker or a reporter gene present on the replicon.
A "clone" refers to a population of cells derived from a single cell or common ancestor generally by the process of mitosis.
EXAMPLES
The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
Example 1 Construction of Plasmids The NS3 protease replicon shuttle vectors were derived from the HCV replicon shuttle vector, pSC_lb NS3_EcoRV which is an intermediate vector used to generate the replicon shuttle vector, pSC_lbNS3_EcoRV Xbal, and is disclosed in US patent application, USSN 60/995,558, filed on September 27, 2007 by Chua et al., entitled "HCV NS3 Replicon Shuttle Vectors", which is incorporated by reference in full herein. The components of the replicon shuttle vectors are shown in Figure 1 and contain the HCV
polynucleotide sequence from the 5'-UTR, NS3 through NS5B proteins and the 3'-UTR. The vectors also include the poliovirus internal ribosome entry site (IRES), which controls the translation of a firefly luciferase gene. Downstream of the firefly luciferase gene, the IRES from the encephalomyocarditis virus (EMCV) controls the translation of the HCV non-structural genes (NS3, NS4A, NS4B, NS5A and NS5B).
Mutations were introduced into pSC_lb_NS3_EcoRV_Xbal using the QuickChange site-directed mutagenesis kit following the manufacturers' instructions (Stratagene, La Jolla, CA, USA). To introduce an AsiSI restriction enzyme sequence at the 3' end of the protease domain of the NS3 gene (corresponding to amino acid position Ser 181), the following primers were used:
Sense primer 5'-GAGTCTATGGGAACCACTATGCGATCGCCGGTCTTCAC
GGACAACTCGTC-3' (SEQ ID NO:1) Anti-sense primer 5'-GACGAGTTGTCCGTGAAGACCGGCGATCGCATAGTGG
TTCCCATAGACTC-3' (SEQ ID NO:2) These mutations did not change the amino acid coding sequence of the NS3 protein and resulted in the generation of the NS3 protease shuttle vector, pSC_lb_NS3/Protease_EcoRV_AsiSl (SEQ ID NO:3, Figure 2A). Another NS3 protease replicon shuttle vector was generated whereby the sequence encoding the protease domain of the NS3 gene was replaced by the beta-galactosidase (lacZ) coding sequence from pUC19 (GenBank Accession Number M77789). An EcoRV restriction site at the 5' end and an AsiSI restriction site at the 3' end of the lacZ gene were introduced by PCR
amplification using the following primers 5'-ATCATCATC GATATC ACC GCGTTGGCCGATTCATTAATG-3' (SEQ ID NO:4) (EcoRV) (LacZ) 5'-GATGATGAT GCGATCGC CAGCTCCCGGAGACGGTCAC-3' (SEQ ID NO:5) (AsiSI) (LacZ) to generate the vector, pSC_lbNS3/Protease/LacZ_EcoRV_AsiSI (SEQ ID NO:6, Figure 2B).
Replication capability of the NS3 protease replicon shuttle vectors was assessed using the phenotypic assay described in Example 3 (and shown in Figure 3).
Example 2 Cloning of the NS3 protease domain PCR samples amplified from infected patients into the NS3 protease replicon shuttle vectors DNA sequences encoding the protease domain of the NS3 gene were generated by reverse transcription-polymerase chain reaction (RT-PCR) of RNA from plasma obtained from patients infected with HCV genotype-la and genotype 1-b using the SuperScript III system (Invitrogen) according to the manufacturer's protocol. The primers used for this RT-PCR
step were the following.
Genotype 1 a:
Sense primer (NS2) 5'-CGTGCGGTGACATCATCAACGG-3' (SEQ ID NO:7) Antisense primer (NS3/helicase) 5' -CTCGCCCCCGCAGTCTCTGC-3' (SEQ ID NO:8) Genotype lb:
Sense primer (NS2) 5' -GAGACCAAGATCATCACCTGG-3' (SEQ ID NO:9) Antisense primer (NS3/helicase) 5' -GTCCAGGACTGTGCCGATGCC-3' (SEQ ID NO:l0) Annealing was first done at 50 C and was followed by PCR cycles of denaturation at 94 C, annealing at 53 C and extension at 68 C. The amplified products were then subjected to a second round of PCR with the PhusionTM High-Fidelity DNA Polymerase system (New England Biolabs) using primers that introduce unique restriction enzyme sequences at the 5' and 3' ends of the protease domain of the NS3 protein. Sense primers used to introduce the EcoRV restriction enzyme sequence near the 5' end of the patient NS3 gene sequence were as follows:
Genotype 1 a 5'-CTGTCTGTCTGATATCACCATGGCGCCCATCACGGCGTACGCC-3' (SEQ ID NO:11) Genotype lb 5'-CTGTCTGTCTGATATCACCATGGCGCCTATTACGGCCTACTC-3' (SEQ ID NO: 12) Antisense primers used to introduce the AsiSI restriction enzyme sequence near the 3' end (corresponding to amino acid position Serl8l) of the protease domain of the NS3 gene sequence were as follows:
Genotype 1 a 5' -TAGTAGTAGGCGATCGCATGGTTGTCCCTAGGTTCTC-3' (SEQ ID NO:13) Genotype lb 5' -TAGTAGTAGGCGATCGCATAGTGGTTCCCATAGACTCG-3' (SEQ ID NO:14) Amplification was carried out for PCR cycles with denaturation at 98 C, annealing at 53 C
and extension at 72 C. The amplified patient NS3 protease DNA were then purified using Qiagen PCR Purification Columns and digested with EcoRV and Sgfl (isoschizomer of AsiSI).
The NS3 protease shuttle replicon vectors, pSC_lbNS3/protease_EcoRV_AsiSI or pSC_lbNS3/protease/LacZ_EcoRV_AsiSI were prepared by double digestion with restriction endonucleaseas, EcoRV and Sgfl. Twenty-five ng of shuttle vector were ligated with the digested patient amplicons using MightMix ligation kit (Takara Bio Inc.) for 1.5 hours at 16 C. Vector to insert ratio of 1:2 to 1:4 were routinely used. 5 gl of the reaction were transformed into 50 gl of Topl O Cells (Invitrogen) and plated after 1 hour of phenotypic expression at 37 C.
96 individual colonies were picked to inoculate 200 gl of Terrific Broth (TB) supplemented with 50 gg/ml ampicillin. This "stock" 96-well plate was incubated overnight at 37 C. The next day, this plate was used to prepare a replica plate. A 48 pin stamp was used to replica plate onto two LB plates supplemented with 100 gg/ml carbenicillin. The 96 individual 200 gl cultures were also transferred into 1.5 ml TB cultures supplemented with 50 gg/ml ampicillin to be used for DNA preparation. After an overnight incubation at 37 C, the replica plate was spread with 6 mis of LB to obtain a heterogeneous pool of 96 clones, which was then used for mini-DNA preps. This DNA patient pool was then used for the subsequent Replicon Phenotypic Assay. After overnight shaking at 37 C, the 96 individual 1.5 ml TB
cultures were spun down, decanted and plasmid DNA was extracted using Qiagen's Qiaprep 96 Turbo Mini-DNA Kit. These individual molecular clones, which represent the composite 96 pool used for the Replicon Phenotypic Assay, were used for sequencing reactions.
Heterogeneous clone pool plasmid DNAs or individual molecular clones were submitted to sequencing to confirm the identity of patient samples and to examine sensitivity to inhibitors in the Phenotypic Replicon Assay.
Example 3 Phenotypic Replicon Assay A. Preparation of in vitro transcribed RNA
Five micrograms of DNA plasmids were linearized by Sea I restriction enzyme (Roche).
After overnight digestion at 37 C, the DNA was purified using Qiagen PCR
purification kit.
One microgram of linearized DNA was used for the in vitro transcription using T7 RiboMAX
Express (Promega) following manufacturer's protocol. After 2 hours of incubation at 37 C, DNase treatment was performed for 30 minutes at 37 C to remove the DNA
template. In vitro transcribed RNA was then purified using RNeasy spin column (Qiagen) following manufacturer's protocol.
B. Hepatoma cell line The hepatoma Lunet Huh-7 cell line were cultured at 37 C in a humidified atmosphere with 5 % CO2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with GlutamaxTM
and 100 mg/ml sodium pyruvate. The medium was further supplemented with 10 % (v/v) FBS
and 1 % (v/v) penicillin/streptomycin. All reagents were from Invitrogen/Gibco.
C. Determination of transient replicons replication level Four million Lunet Huh7 cells were transfected with 5 .tg of in vitro transcribed RNA using electroporation. Cells were then resuspended in 7.2 ml of DMEM containing 5 %
FBS and plated in 96-well plate at 50000 cells/well (in 90 1 final volume). Inhibitors (when used) were added 24 hours post-transfection in 3 fold dilutions at a final DMSO
concentration of 1 %
A "clone" refers to a population of cells derived from a single cell or common ancestor generally by the process of mitosis.
EXAMPLES
The following preparations and examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.
Example 1 Construction of Plasmids The NS3 protease replicon shuttle vectors were derived from the HCV replicon shuttle vector, pSC_lb NS3_EcoRV which is an intermediate vector used to generate the replicon shuttle vector, pSC_lbNS3_EcoRV Xbal, and is disclosed in US patent application, USSN 60/995,558, filed on September 27, 2007 by Chua et al., entitled "HCV NS3 Replicon Shuttle Vectors", which is incorporated by reference in full herein. The components of the replicon shuttle vectors are shown in Figure 1 and contain the HCV
polynucleotide sequence from the 5'-UTR, NS3 through NS5B proteins and the 3'-UTR. The vectors also include the poliovirus internal ribosome entry site (IRES), which controls the translation of a firefly luciferase gene. Downstream of the firefly luciferase gene, the IRES from the encephalomyocarditis virus (EMCV) controls the translation of the HCV non-structural genes (NS3, NS4A, NS4B, NS5A and NS5B).
Mutations were introduced into pSC_lb_NS3_EcoRV_Xbal using the QuickChange site-directed mutagenesis kit following the manufacturers' instructions (Stratagene, La Jolla, CA, USA). To introduce an AsiSI restriction enzyme sequence at the 3' end of the protease domain of the NS3 gene (corresponding to amino acid position Ser 181), the following primers were used:
Sense primer 5'-GAGTCTATGGGAACCACTATGCGATCGCCGGTCTTCAC
GGACAACTCGTC-3' (SEQ ID NO:1) Anti-sense primer 5'-GACGAGTTGTCCGTGAAGACCGGCGATCGCATAGTGG
TTCCCATAGACTC-3' (SEQ ID NO:2) These mutations did not change the amino acid coding sequence of the NS3 protein and resulted in the generation of the NS3 protease shuttle vector, pSC_lb_NS3/Protease_EcoRV_AsiSl (SEQ ID NO:3, Figure 2A). Another NS3 protease replicon shuttle vector was generated whereby the sequence encoding the protease domain of the NS3 gene was replaced by the beta-galactosidase (lacZ) coding sequence from pUC19 (GenBank Accession Number M77789). An EcoRV restriction site at the 5' end and an AsiSI restriction site at the 3' end of the lacZ gene were introduced by PCR
amplification using the following primers 5'-ATCATCATC GATATC ACC GCGTTGGCCGATTCATTAATG-3' (SEQ ID NO:4) (EcoRV) (LacZ) 5'-GATGATGAT GCGATCGC CAGCTCCCGGAGACGGTCAC-3' (SEQ ID NO:5) (AsiSI) (LacZ) to generate the vector, pSC_lbNS3/Protease/LacZ_EcoRV_AsiSI (SEQ ID NO:6, Figure 2B).
Replication capability of the NS3 protease replicon shuttle vectors was assessed using the phenotypic assay described in Example 3 (and shown in Figure 3).
Example 2 Cloning of the NS3 protease domain PCR samples amplified from infected patients into the NS3 protease replicon shuttle vectors DNA sequences encoding the protease domain of the NS3 gene were generated by reverse transcription-polymerase chain reaction (RT-PCR) of RNA from plasma obtained from patients infected with HCV genotype-la and genotype 1-b using the SuperScript III system (Invitrogen) according to the manufacturer's protocol. The primers used for this RT-PCR
step were the following.
Genotype 1 a:
Sense primer (NS2) 5'-CGTGCGGTGACATCATCAACGG-3' (SEQ ID NO:7) Antisense primer (NS3/helicase) 5' -CTCGCCCCCGCAGTCTCTGC-3' (SEQ ID NO:8) Genotype lb:
Sense primer (NS2) 5' -GAGACCAAGATCATCACCTGG-3' (SEQ ID NO:9) Antisense primer (NS3/helicase) 5' -GTCCAGGACTGTGCCGATGCC-3' (SEQ ID NO:l0) Annealing was first done at 50 C and was followed by PCR cycles of denaturation at 94 C, annealing at 53 C and extension at 68 C. The amplified products were then subjected to a second round of PCR with the PhusionTM High-Fidelity DNA Polymerase system (New England Biolabs) using primers that introduce unique restriction enzyme sequences at the 5' and 3' ends of the protease domain of the NS3 protein. Sense primers used to introduce the EcoRV restriction enzyme sequence near the 5' end of the patient NS3 gene sequence were as follows:
Genotype 1 a 5'-CTGTCTGTCTGATATCACCATGGCGCCCATCACGGCGTACGCC-3' (SEQ ID NO:11) Genotype lb 5'-CTGTCTGTCTGATATCACCATGGCGCCTATTACGGCCTACTC-3' (SEQ ID NO: 12) Antisense primers used to introduce the AsiSI restriction enzyme sequence near the 3' end (corresponding to amino acid position Serl8l) of the protease domain of the NS3 gene sequence were as follows:
Genotype 1 a 5' -TAGTAGTAGGCGATCGCATGGTTGTCCCTAGGTTCTC-3' (SEQ ID NO:13) Genotype lb 5' -TAGTAGTAGGCGATCGCATAGTGGTTCCCATAGACTCG-3' (SEQ ID NO:14) Amplification was carried out for PCR cycles with denaturation at 98 C, annealing at 53 C
and extension at 72 C. The amplified patient NS3 protease DNA were then purified using Qiagen PCR Purification Columns and digested with EcoRV and Sgfl (isoschizomer of AsiSI).
The NS3 protease shuttle replicon vectors, pSC_lbNS3/protease_EcoRV_AsiSI or pSC_lbNS3/protease/LacZ_EcoRV_AsiSI were prepared by double digestion with restriction endonucleaseas, EcoRV and Sgfl. Twenty-five ng of shuttle vector were ligated with the digested patient amplicons using MightMix ligation kit (Takara Bio Inc.) for 1.5 hours at 16 C. Vector to insert ratio of 1:2 to 1:4 were routinely used. 5 gl of the reaction were transformed into 50 gl of Topl O Cells (Invitrogen) and plated after 1 hour of phenotypic expression at 37 C.
96 individual colonies were picked to inoculate 200 gl of Terrific Broth (TB) supplemented with 50 gg/ml ampicillin. This "stock" 96-well plate was incubated overnight at 37 C. The next day, this plate was used to prepare a replica plate. A 48 pin stamp was used to replica plate onto two LB plates supplemented with 100 gg/ml carbenicillin. The 96 individual 200 gl cultures were also transferred into 1.5 ml TB cultures supplemented with 50 gg/ml ampicillin to be used for DNA preparation. After an overnight incubation at 37 C, the replica plate was spread with 6 mis of LB to obtain a heterogeneous pool of 96 clones, which was then used for mini-DNA preps. This DNA patient pool was then used for the subsequent Replicon Phenotypic Assay. After overnight shaking at 37 C, the 96 individual 1.5 ml TB
cultures were spun down, decanted and plasmid DNA was extracted using Qiagen's Qiaprep 96 Turbo Mini-DNA Kit. These individual molecular clones, which represent the composite 96 pool used for the Replicon Phenotypic Assay, were used for sequencing reactions.
Heterogeneous clone pool plasmid DNAs or individual molecular clones were submitted to sequencing to confirm the identity of patient samples and to examine sensitivity to inhibitors in the Phenotypic Replicon Assay.
Example 3 Phenotypic Replicon Assay A. Preparation of in vitro transcribed RNA
Five micrograms of DNA plasmids were linearized by Sea I restriction enzyme (Roche).
After overnight digestion at 37 C, the DNA was purified using Qiagen PCR
purification kit.
One microgram of linearized DNA was used for the in vitro transcription using T7 RiboMAX
Express (Promega) following manufacturer's protocol. After 2 hours of incubation at 37 C, DNase treatment was performed for 30 minutes at 37 C to remove the DNA
template. In vitro transcribed RNA was then purified using RNeasy spin column (Qiagen) following manufacturer's protocol.
B. Hepatoma cell line The hepatoma Lunet Huh-7 cell line were cultured at 37 C in a humidified atmosphere with 5 % CO2 in Dulbecco's Modified Eagle Medium (DMEM) supplemented with GlutamaxTM
and 100 mg/ml sodium pyruvate. The medium was further supplemented with 10 % (v/v) FBS
and 1 % (v/v) penicillin/streptomycin. All reagents were from Invitrogen/Gibco.
C. Determination of transient replicons replication level Four million Lunet Huh7 cells were transfected with 5 .tg of in vitro transcribed RNA using electroporation. Cells were then resuspended in 7.2 ml of DMEM containing 5 %
FBS and plated in 96-well plate at 50000 cells/well (in 90 1 final volume). Inhibitors (when used) were added 24 hours post-transfection in 3 fold dilutions at a final DMSO
concentration of 1 %
and firefly luciferase reporter signal was read 72 hours after addition of inhibitors using the Luciferase Assay system (Promega). The IC50 values were assessed as the inhibitor concentration at which a 50 % reduction in the level of firefly luciferase reporter was observed as compared to the level of firefly luciferase signal without the addition of compounds.
The replication capacity of the replicon shuttle vector, pSC_lb_NS3/Protease_EcoRV_AsiSI, as well as those of replicons that contain HCV genotype-la and genotype-lb patient-derived NS3 protease domains were tested with the luciferase signal as the readout and the results are shown on Figure 3. The inhibitory effects of the HCV protease inhibitors, BILN2061, VX-950 and NMI 07 were also tested on these replicons and the results are shown on Table 1.
Genotype Replicon Mean IC50 Control or Patient Sample Number BILN2061 VX-950 NM107 nM nM M
pSC_1 b_NS3/Protease_EcoRV_AsiSl 0.489 0.160 0.283 GT-1a RO-191 0.798 0.057 0.539 GT-1a RO-192 0.340 0.068 0.554 GT-1a RO-193 0.298 0.132 0.640 GT-1a RO-194 0.665 0.052 0.509 GT-1a RO-195 0.629 0.028 0.312 GT-1a RO-207 0.386 0.083 1.162 GT-1 b PC232 0.468 0.166 0.449 GT-1 b 206 0.643 0.175 0.279 GT-1 b 301 0.378 0.162 0.279
The replication capacity of the replicon shuttle vector, pSC_lb_NS3/Protease_EcoRV_AsiSI, as well as those of replicons that contain HCV genotype-la and genotype-lb patient-derived NS3 protease domains were tested with the luciferase signal as the readout and the results are shown on Figure 3. The inhibitory effects of the HCV protease inhibitors, BILN2061, VX-950 and NMI 07 were also tested on these replicons and the results are shown on Table 1.
Genotype Replicon Mean IC50 Control or Patient Sample Number BILN2061 VX-950 NM107 nM nM M
pSC_1 b_NS3/Protease_EcoRV_AsiSl 0.489 0.160 0.283 GT-1a RO-191 0.798 0.057 0.539 GT-1a RO-192 0.340 0.068 0.554 GT-1a RO-193 0.298 0.132 0.640 GT-1a RO-194 0.665 0.052 0.509 GT-1a RO-195 0.629 0.028 0.312 GT-1a RO-207 0.386 0.083 1.162 GT-1 b PC232 0.468 0.166 0.449 GT-1 b 206 0.643 0.175 0.279 GT-1 b 301 0.378 0.162 0.279
Claims (34)
1. An HCV replicon shuttle vector comprising an HCV polynucleotide sequence that comprises, in order:
(a) a unique restriction enzyme sequence placed between 10 nucleotides 5' and nucleotides 3' from the 5' end of a polynucleotide sequence encoding a NS3 protein;
(b) a polynucleotide sequence encoding the protease domain of the NS3 protein;
(c) a unique restriction enzyme sequence placed between 10 nucleotides 5' and nucleotides 3' from the 3' end of the polynucleotide sequence encoding the protease domain of the NS3 protein;
(d) a polynucleotide sequence encoding the helicase domain of the NS3 protein;
(e) a polynucleotide sequence encoding a NS4A protein;
(f) a polynucleotide sequence encoding a NS4B protein;
(g) a polynucleotide sequence encoding a NS5A protein; and (h) a polynucleotide sequence encoding a NS5B protein.
(a) a unique restriction enzyme sequence placed between 10 nucleotides 5' and nucleotides 3' from the 5' end of a polynucleotide sequence encoding a NS3 protein;
(b) a polynucleotide sequence encoding the protease domain of the NS3 protein;
(c) a unique restriction enzyme sequence placed between 10 nucleotides 5' and nucleotides 3' from the 3' end of the polynucleotide sequence encoding the protease domain of the NS3 protein;
(d) a polynucleotide sequence encoding the helicase domain of the NS3 protein;
(e) a polynucleotide sequence encoding a NS4A protein;
(f) a polynucleotide sequence encoding a NS4B protein;
(g) a polynucleotide sequence encoding a NS5A protein; and (h) a polynucleotide sequence encoding a NS5B protein.
2. The HCV replicon shuttle vector of claim 1 wherein the polynucleotide sequence encoding the protease domain of the NS3 protein has been modified or deleted such that the protease domain of the NS3 protein is non-functional.
3. The HCV replicon shuttle vector of claim 1 or claim 2 wherein the unique restriction enzyme sequence at the 5' end of the polynucleotide sequence encoding the NS3 protein recognizes EcoRV and the unique restriction enzyme sequence at the 3' end of the polynucleotide sequence encoding the protease domain of the NS3 protein recognizes AsiSI.
4. An HCV replicon shuttle vector comprising an HCV polynucleotide sequence selected from SEQ ID NO:3 or SEQ ID NO:6.
5. A method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of:
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs; and (e) transfecting a Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs; and (e) transfecting a Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
6. The method of claim 5 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 1.
7. The method of claim 5 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 2.
8. The method of claim 5 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 3.
9. The method of claim 5 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 4.
10. A method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of:
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a restriction enzyme sequence that recognizes EcoRV, and an anti-sense strand primer which comprises a restriction enzyme sequence that recognizes AsiSI;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs; and (e) transfecting a Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a restriction enzyme sequence that recognizes EcoRV, and an anti-sense strand primer which comprises a restriction enzyme sequence that recognizes AsiSI;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs; and (e) transfecting a Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
11. The method of claim 10 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 1.
12. The method of claim 10 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 2.
13. The method of claim 5 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 3.
14. The method of claim 5 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 4.
15. A method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of:
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer comprising a nucleotide sequence selected from SEQ ID NO:11 or SEQ ID NO:12, and an anti-sense strand primer comprising a nucleotide selected from SEQ ID NO:13 or SEQ ID
NO:14;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs; and (e) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer comprising a nucleotide sequence selected from SEQ ID NO:11 or SEQ ID NO:12, and an anti-sense strand primer comprising a nucleotide selected from SEQ ID NO:13 or SEQ ID
NO:14;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) linearizing said chimeric HCV replicon plasmids and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV replicon RNAs; and (e) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
16. The method of claim 15 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 1.
17. The method of claim 15 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 2.
18. The method of claim 15 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 3.
19. The method of claim 15 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 4.
20. A method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of:
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) transforming said plasmids into cells to generate a plurarity of colonies of transformed cells;
(e) pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies;
(f) linearizing said chimeric HCV replicon plasmids from step (e) and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV
replicon RNAs; and (g) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a unique restriction enzyme sequence, and an anti-sense strand primer which comprises a different unique restriction enzyme sequence;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) transforming said plasmids into cells to generate a plurarity of colonies of transformed cells;
(e) pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies;
(f) linearizing said chimeric HCV replicon plasmids from step (e) and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV
replicon RNAs; and (g) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
21. The method of claim 20 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 1.
22. The method of claim 20 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 2.
23. The method of claim 20 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 3.
24. The method of claim 20 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 4.
25. A method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of:
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a restriction enzyme sequence that recognizes EcoRV, and an anti-sense strand primer which comprises a restriction enzyme sequence that recognizes AsiSI;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) transforming said plasmids into cells to generate a plurarity of colonies of transformed cells;
(e) pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies;
(f) linearizing said chimeric HCV replicon plasmids from step (e) and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV
replicon RNAs; and (g) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer which comprises a restriction enzyme sequence that recognizes EcoRV, and an anti-sense strand primer which comprises a restriction enzyme sequence that recognizes AsiSI;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) transforming said plasmids into cells to generate a plurarity of colonies of transformed cells;
(e) pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies;
(f) linearizing said chimeric HCV replicon plasmids from step (e) and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV
replicon RNAs; and (g) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
26. The method of claim 25 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 1.
27. The method of claim 25 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 2.
28. The method of claim 25 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 3.
29. The method of claim 25 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 4.
30. A method for assessing the effectiveness of an HCV NS3 protease inhibitor to control an HCV infection in a subject comprising the steps of:
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer comprising a nucleotide sequence selected from SEQ ID NO:11 or SEQ ID NO:12, and an anti-sense strand primer comprising a nucleotide selected from SEQ ID NO:13 or SEQ ID
NO:14;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) transforming said plasmids into cells to generate a plurarity of colonies of transformed cells;
(e) pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies;
(f) linearizing said chimeric HCV replicon plasmids from step (e) and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV
replicon RNAs; and (g) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
(a) providing a sample from the subject infected with HCV;
(b) PCR-amplifying polynucleotide sequences encoding the protease domain of the NS3 protein from a plurarity of HCV quasispecies present in the sample with the use of a sense-strand primer comprising a nucleotide sequence selected from SEQ ID NO:11 or SEQ ID NO:12, and an anti-sense strand primer comprising a nucleotide selected from SEQ ID NO:13 or SEQ ID
NO:14;
(c) cloning said PCR-amplifed polynucleotide sequences into an HCV replicon shuttle vector to produce chimeric HCV replicon plasmids;
(d) transforming said plasmids into cells to generate a plurarity of colonies of transformed cells;
(e) pooling said colonies and isolating chimeric HCV replicon plasmids from the pooled colonies;
(f) linearizing said chimeric HCV replicon plasmids from step (e) and subjecting said linearized plasmids to in vitro transcription to produce chimeric HCV
replicon RNAs; and (g) transfecting Huh7 cell line with said HCV replicon RNAs and measuring replication level of said HCV replicon RNAs in the presence or absence of the HCV NS3 protease inhibitor.
31. The method of claim 30 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 1.
32. The method of claim 30 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 2.
33. The method of claim 30 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 3.
34. The method of claim 30 wherein the HCV replicon shuttle vector of step (c) comprises the HCV replicon shuttle vector of claim 4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US579207P | 2007-12-07 | 2007-12-07 | |
| US61/005,792 | 2007-12-07 | ||
| PCT/EP2008/066417 WO2009071488A2 (en) | 2007-12-07 | 2008-11-28 | Hcv ns3 protease replicon shuttle vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2706659A1 true CA2706659A1 (en) | 2009-06-11 |
Family
ID=40451400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2706659A Abandoned CA2706659A1 (en) | 2007-12-07 | 2008-11-28 | Hcv ns3 protease replicon shuttle vectors |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2220226A2 (en) |
| JP (1) | JP2011505159A (en) |
| KR (1) | KR20100084689A (en) |
| CN (1) | CN101889085A (en) |
| AU (1) | AU2008333339A1 (en) |
| BR (1) | BRPI0821155A2 (en) |
| CA (1) | CA2706659A1 (en) |
| IL (1) | IL205340A0 (en) |
| MX (1) | MX2010005752A (en) |
| WO (1) | WO2009071488A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011023801A1 (en) * | 2009-08-31 | 2011-03-03 | F. Hoffmann-La Roche Ag | Hcv ns3/4a replicon shuttle vectors |
| US20110245328A1 (en) * | 2010-03-31 | 2011-10-06 | Hyunsoon Kang | HCV NS5A Replicon Shuttle Vectors |
| MX2014000124A (en) * | 2011-07-06 | 2014-02-17 | Gilead Sciences Inc | Hcv genotype 3 replicons. |
| EP2729490A1 (en) * | 2011-07-06 | 2014-05-14 | Gilead Sciences, Inc. | Hcv genotype 4 replicons |
| JP6562908B2 (en) | 2013-10-11 | 2019-08-21 | ヤンセン バイオファーマ インク． | Substituted nucleosides, substituted nucleotides and analogs thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1801116A1 (en) * | 2005-12-21 | 2007-06-27 | F. Hoffmann-La Roche Ag | HCV replicon shuttle vectors |
-
2008
- 2008-11-28 JP JP2010536414A patent/JP2011505159A/en active Pending
- 2008-11-28 KR KR1020107012332A patent/KR20100084689A/en not_active Application Discontinuation
- 2008-11-28 AU AU2008333339A patent/AU2008333339A1/en not_active Abandoned
- 2008-11-28 BR BRPI0821155A patent/BRPI0821155A2/en not_active IP Right Cessation
- 2008-11-28 CN CN2008801195086A patent/CN101889085A/en active Pending
- 2008-11-28 CA CA2706659A patent/CA2706659A1/en not_active Abandoned
- 2008-11-28 EP EP08857414A patent/EP2220226A2/en not_active Withdrawn
- 2008-11-28 MX MX2010005752A patent/MX2010005752A/en unknown
- 2008-11-28 WO PCT/EP2008/066417 patent/WO2009071488A2/en active Application Filing
-
2010
- 2010-04-26 IL IL205340A patent/IL205340A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010005752A (en) | 2010-06-15 |
| WO2009071488A2 (en) | 2009-06-11 |
| KR20100084689A (en) | 2010-07-27 |
| JP2011505159A (en) | 2011-02-24 |
| IL205340A0 (en) | 2010-12-30 |
| WO2009071488A3 (en) | 2009-09-24 |
| BRPI0821155A2 (en) | 2019-09-24 |
| AU2008333339A1 (en) | 2009-06-11 |
| CN101889085A (en) | 2010-11-17 |
| EP2220226A2 (en) | 2010-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8754061B2 (en) | Nucleic acid construct containing a nucleic acid derived from the genome of hepatitis C virus (HCV) of genotype 2a, and a cell having such nucleic acid construct introduced therein | |
| EP1801209B1 (en) | Modified human hepatitis c virus genomic rna having autonomous replicative competence | |
| EP1801116A1 (en) | HCV replicon shuttle vectors | |
| CA2706659A1 (en) | Hcv ns3 protease replicon shuttle vectors | |
| US20100068698A1 (en) | Production of infectious hepatitis c virus particles in cell culture | |
| JP4573776B2 (en) | Nucleic acid and gene derived from a novel HCV strain, and replicon-replicating cells using the gene | |
| US20090004664A1 (en) | HCV NS3 replicon shuttle vectors | |
| US20110053160A1 (en) | Hcv ns3/4a replicon shuttle vectors | |
| US20100173281A1 (en) | HCV NS3 protease replicon shuttle vectors | |
| WO2011023801A1 (en) | Hcv ns3/4a replicon shuttle vectors | |
| US20110245328A1 (en) | HCV NS5A Replicon Shuttle Vectors | |
| US8609403B2 (en) | Polynucleotide derived from novel hepatitis C virus strain and use thereof | |
| EP1360276A2 (en) | In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses | |
| US7790448B2 (en) | Nucleic acid and gene derived from novel HCV strain and replicon-replicating cell using said gene |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20121128 |